수술 및 항암 방사선 치료에 실패 후 표적 치료로 완전 관해를 유도한 비강 저분화형 암종 1예
A Case of Complete Remission of Nasal Cavity Poorly Differentiated Carcinoma With Targeted Therapy, to Which Surgery and Concurrent Chemoradiotherapy Was Ineffective
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Nasal cavity and paranasal sinus cancers comprise about 1% of all malignancies, and 5% ofhead and neck malignancy. Squamous cell carcinoma comprises more than half of nasal cavi-ty cancers. Treatment is determined by considering tumor size, location, staging, age, generalcondition, purpose of treatment, etc. Conventional therapy includes surgery, radiotherapy, andchemotherapy; however, for the locally advanced, recurrent, or metastatic cancer after con-ventional therapy, immunotherapy or targeted therapy are taken into consideration. Targettherapy attacks specific cancer cells directly, such as cancer cells with certain gene mutation,whereas immunotherapy attacks cancer cells indirectly, stimulating our own immune system,such as T-cell activity. Histologically poorly differentiated carcinomas are treated with sur-gery, radiotherapy, and sometimes chemotherapy, but 5-year survival rate is low due to fre-quent recurrence. Here, we present a case of successful targeted therapy applied to recurrentnasal cavity cancer after serial application of conventional therapies.
Abstract
Nasal cavity and paranasal sinus cancers comprise about 1% of all malignancies, and 5% ofhead and neck malignancy. Squamous cell carcinoma comprises more than half of nasal cavi-ty cancers. Treatment is determined by considering tumor size, location, staging, age, generalcondition, purpose of treatment, etc. Conventional therapy includes surgery, radiotherapy, andchemotherapy; however, for the locally advanced, recurrent, or metastatic cancer after con-ventional therapy, immunotherapy or targeted therapy are taken into consideration. Targettherapy attacks specific cancer cells directly, such as cancer cells with certain gene mutation,whereas immunotherapy attacks cancer cells indirectly, stimulating our own immune system,such as T-cell activity. Histologically poorly differentiated carcinomas are treated with sur-gery, radiotherapy, and sometimes chemotherapy, but 5-year survival rate is low due to fre-quent recurrence. Here, we present a case of successful targeted therapy applied to recurrentnasal cavity cancer after serial application of conventional therapies.
참고문헌 (15)
- Sjöstedt S, "Incidence and survival in sinonasal carcinoma: A Danish population-based, nationwide study from 1980 to 2014", Acta Oncol, 57(9), pp.1152~1158 (2018)
- Ackall FY, "Survival outcomes in sinonasal poorly differentiated squamous cell carcinoma", Laryngoscope, 131(4), pp.E1040~8 (2021)
- Glisson BS, "Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck", J Clin Oncol, 20(6), pp.1593~1599 (2002)
- Kazi M, "Management of sinonasal tumors : Prognostic factors and outcomes : A 10 year experience at a tertiary care hospital", Indian J Otolaryngol Head Neck Surg, 65(Suppl 1), pp.155~159 (2013)
- Bugra Cengiz A, "Sinonasal tract malignancies : Prognostic factors and surgery outcomes", Iran Red Crescent Med J, 15(12), pp.e14118~ (2013)
- Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck", N Engl J Med, 354(6), pp.567~578 (2006)
- Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359(11), pp.1116~1127 (2008)
- Agarwal V, "Is EGFR really a therapeutic target in head and neck cancers?", J Surg Oncol, 119(6), pp.685~686 (2019)
- Bonner JA, "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival", Lancet Oncol, 11(1), pp.21~28 (2010)
- Mei Z, "Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma", Int J Oral Sci, 12(1), pp.16~ (2020)
- Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375(19), pp.1856~1867 (2016)
- Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):A randomised, open-label, phase 3 study", Lancet, 394(10212), pp.1915~1928 (2019)
- Kitamura N, "Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma", Int J Mol Sci, 22(1), pp.240~ (2020)
- McCormack PL, "Nintedanib : First global approval", Drugs, 75(1), pp.129~139 (2015)
- Kim Y, "Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck : A multicenter phase 2 study(Korean Cancer Study Group HN14-01)", Cancer, 123(11), pp.1958~1964 (2017)